Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Carbogen Buys French Finished-Dosage Firm
by Rick Mullin
January 23, 2012
| A version of this story appeared in
Volume 90, Issue 4
Carbogen Amcis, a Swiss pharmaceutical chemical firm, has acquired Creapharm Parenterals, a division of France’s Creapharm involved in the contract manufacture of finished-dose drugs. The deal will allow Carbogen to provide customers with services “from process development to the supply of pharmaceutical substances and formulated products,” says CEO Mark Griffiths. Fine chemicals makers such as Cambrex and Albany Molecular Research Inc. also have added drug formulation capabilities to their service offerings.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter